Literature DB >> 23538206

Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.

Amy K Goodwin1, K Michael Gibson, Elise M Weerts.   

Abstract

BACKGROUND: 1,4-Butanediol (1,4-BD) is a gamma-hydroxybutyrate (GHB) pro-drug, with multiple commercial uses, and a drug of abuse. Although there are case reports of a withdrawal syndrome following 1,4-BD use, no studies have evaluated the physical dependence potential of 1,4-BD and characterized the time course of withdrawal.
METHODS: Vehicle and then 1,4-BD were administered continuously 24 h/day via intragastric catheters in male baboons (Papio anubis, n=3). Dosing was initiated at 100 mg/kg and increased by 100mg/kg/day to 400mg/kg. After a stabilization period, doses of 500 and then 600 mg/kg/day were each maintained for 3-4 weeks. Plasma levels of 1,4-BD and GHB were determined for each dose condition. Physical dependence was assessed via administration of a GABA-B antagonist (precipitated withdrawal test) during administration of the 600 mg/kg dose and via abrupt termination of chronic 1,4-BD administration (spontaneous withdrawal test). Outcome measures included the number of food pellets earned, performance on a fine-motor task, observed behaviors, and plasma levels of GHB and 1,4-BD.
RESULTS: Following maintenance of 1,4-BD 600 mg/kg for 3 weeks, the number of food pellets earned was significantly decreased. At the end of chronic 1,4-BD dosing, the levels of GHB in plasma ranged from 1290 to 2300 μmol/L and levels of 1,4-BD in plasma ranged from 13.1 to 37.9 μmol/L. Signs of physical dependence were observed following precipitated and spontaneous withdrawal tests. Seizures were not observed.
CONCLUSIONS: These data indicate chronic 1,4-BD produced physical dependence in baboons and the withdrawal syndrome can be characterized as mild to intermediate.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  GABA-B receptor antagonists; GHB; Operant behavior; Withdrawal

Mesh:

Substances:

Year:  2013        PMID: 23538206      PMCID: PMC3718862          DOI: 10.1016/j.drugalcdep.2013.02.035

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  47 in total

1.  Gamma-hydroxybutyrate detoxification by titration and tapering.

Authors:  Cor A J de Jong; Rama Kamal; Boukje A G Dijkstra; Hein A de Haan
Journal:  Eur Addict Res       Date:  2011-12-03       Impact factor: 3.015

2.  Adverse events, including death, associated with the use of 1,4-butanediol.

Authors:  D L Zvosec; S W Smith; J R McCutcheon; J Spillane; B J Hall; E A Peacock
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

3.  Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys.

Authors:  Lance R McMahon; Andrew Coop; Charles P France; Gail Winger; William L Woolverton
Journal:  Eur J Pharmacol       Date:  2003-04-11       Impact factor: 4.432

4.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

5.  Development of tolerance to and physical dependence on barbiturates in rhesus monkeys.

Authors:  T Yanagita; S Takahashi
Journal:  J Pharmacol Exp Ther       Date:  1970-03       Impact factor: 4.030

Review 6.  GHB: a new and novel drug of abuse.

Authors:  K L Nicholson; R L Balster
Journal:  Drug Alcohol Depend       Date:  2001-06-01       Impact factor: 4.492

7.  Withdrawal syndrome from gamma-hydroxybutyric acid (GHB) and 1,4-butanediol (1,4-BD) in Sardinian alcohol-preferring rats.

Authors:  Mauro A M Carai; Lawrence S Quang; Sergio Atzeri; Carla Lobina; Paola Maccioni; Alessandro Orrù; Gian Luigi Gessa; Timothy J Maher; Giancarlo Colombo
Journal:  Brain Res Brain Res Protoc       Date:  2005-07

Review 8.  A comprehensive review of MDMA and GHB: two common club drugs.

Authors:  C J Teter; S K Guthrie
Journal:  Pharmacotherapy       Date:  2001-12       Impact factor: 4.705

9.  Comparison of the actions of gamma-butyrolactone and 1,4-butanediol in Swiss-Webster mice.

Authors:  Christopher M de Fiebre; Nancy Ellen C de Fiebre; Scott L Coleman; Michael J Forster
Journal:  Pharmacol Biochem Behav       Date:  2004-04       Impact factor: 3.533

Review 10.  Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.

Authors:  Michael McDonough; Noel Kennedy; Anthony Glasper; Jenny Bearn
Journal:  Drug Alcohol Depend       Date:  2004-07-15       Impact factor: 4.492

View more
  5 in total

1.  Impact of strain, sex, and estrous cycle on gamma butyrolactone-evoked absence seizures in rats.

Authors:  Victor R Santos; Ihori Kobayashi; Robert Hammack; Gregory Danko; Patrick A Forcelli
Journal:  Epilepsy Res       Date:  2018-09-18       Impact factor: 3.045

2.  The endocannabinoid system in the baboon (Papio spp.) as a complex framework for developmental pharmacology.

Authors:  Iram P Rodriguez-Sanchez; Josee Guindon; Marco Ruiz; M Elizabeth Tejero; Gene Hubbard; Laura E Martinez-de-Villarreal; Hugo A Barrera-Saldaña; Edward J Dick; Anthony G Comuzzie; Natalia E Schlabritz-Loutsevitch
Journal:  Neurotoxicol Teratol       Date:  2016-06-18       Impact factor: 3.763

Review 3.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 4.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

Review 5.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.